PYCR1 and small cell lung carcinoma: We show that ADORA2A can serve as a promising druggable target that drives a proline metabolic-epigenetic cascade via the ERK/MYC/PYCR axis in NEPC and SCLC, suggesting a broad therapeutic implication of ADORA2A blockade in NE malignancies.